Effect of Dietary Phytochemicals in Obesity and Cancer

Shuaib, Mohd; Kushwaha, Prem Prakash; Prajapati, Kumari Sunita; Singh, Atul Kumar; Sharma, Rahul Kumar; Kumar, Shashank

doi:10.1007/978-981-16-1846-8_9

Cited by 3 publications

(1 citation statement)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obesity and overweight have become a major common health problem globally, experiencing increasing rates in both developed and developing countries (Shao et al 2014). In 2016, it was estimated that 1.9 billion adults were overweight and 650 million out of 1.9 billion overweight were classified as obese (Shuaib et al 2021). The worldwide prevalence of obesity has nearly tripled between 1975(Abarca-Gómez et al 2017.…”

Section: Anti-obesity Activitymentioning

confidence: 99%

Russelioside B: a Pregnane Glycoside with Pharmacological Potential

Abdel‐Sattar

Ali

2022

Rev. Bras. Farmacogn.

View full text Add to dashboard Cite

Pregnanes and pregnane glycosides or their esters are well-studied secondary metabolites, many of them exhibit immunomodulator, anticancer, antidiabetic, antarthritic, antiulcer, anti-nociceptive, hypolipidemic, anti-inflammatory, and antibacterial properties. Pregnane glycosides are widely distributed in the families Apocyanaceae and Asclepiadaceae. Plant members of the genus Caralluma R.Br., Apocynaceae, are among the most studied species because of uses in traditional medicine or as food. They are a rich source of pregnane glycosides, as russelioside B. However, the bioactivity profile of this pregnane glycoside has not been reviewed until now. The present review aims to summarize the most important pharmacological and therapeutic applications of russelioside B with specific emphasis on the mechanism of actions associated with its administration in preclinical models. Russelioside B has many pharmacological effects including antidiabetic, anti-obesity, anti-nociceptive, antiulcer, anti-inflammatory, anti-arthritis effects, and antibiofilm, and wound healing activities. Despite its outstanding pharmacotherapeutic potential, russelioside B has never been tested in clinical trials. This review indicates that russelioside B is a potentially promising bioactive candidate, but further deeper mechanistic studies and clinical trials are needed in the future to elucidate its interaction with receptors of specific genes.

show abstract

Section: Anti-obesity Activitymentioning

confidence: 99%

Russelioside B: a Pregnane Glycoside with Pharmacological Potential

Abdel‐Sattar

Ali

2022

Rev. Bras. Farmacogn.

View full text Add to dashboard Cite

show abstract

Myricetin: a potential plant-derived anticancer bioactive compound—an updated overview

Kumar¹,

Swamy

Tuli

et al. 2023

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

An In-Silico Identification of Potential Flavonoids against Kidney Fibrosis Targeting TGFβR-1

Rahman

Biswas²,

Dey

et al. 2022

Life

View full text Add to dashboard Cite

Fibrosis is a hallmark of progressive kidney diseases. The overexpression of profibrotic cytokine, namely transforming growth factor β (TGF-β) due to excessive inflammation and tissue damage, induces kidney fibrosis. The inhibition of TGF-β signaling is markedly limited in experimental disease models. Targeting TGF-β signaling, therefore, offers a prospective strategy for the management of kidney fibrosis. Presently, the marketed drugs have numerous side effects, but plant-derived compounds are relatively safer and more cost-effective. In this study, TGFβR-1 was targeted to identify the lead compounds among flavonoids using various computational approaches, such as ADME/T (absorption, distribution, metabolism, and excretion/toxicity) analysis, molecular docking, and molecular dynamics simulation. ADME/T screening identified a total of 31 flavonoids with drug-like properties of 31 compounds, a total of 5 compounds showed a higher binding affinity to TGFβR-1, with Epicatechin, Fisetin, and Luteolin ranking at the top three (−13.58, −13.17, and −10.50 kcal/mol, respectively), which are comparable to the control drug linagliptin (−9.074 kcal/mol). The compounds also exhibited outstanding protein–ligand interactions. The molecular dynamic simulations revealed a stable interaction of these compounds with the binding site of TGFβR-1. These findings indicate that flavonoids, particularly Epicatechin, Fisetin, and Luteolin, may compete with the ligand-binding site of TGFβR-1, suggesting that these compounds can be further evaluated for the development of potential therapeutics against kidney fibrosis. Further, in-vitro and in-vivo studies are recommended to support the current findings.

show abstract

Effect of Dietary Phytochemicals in Obesity and Cancer

Cited by 3 publications

References 71 publications

Russelioside B: a Pregnane Glycoside with Pharmacological Potential

Russelioside B: a Pregnane Glycoside with Pharmacological Potential

Myricetin: a potential plant-derived anticancer bioactive compound—an updated overview

An In-Silico Identification of Potential Flavonoids against Kidney Fibrosis Targeting TGFβR-1

Contact Info

Product

Resources

About